Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer by Montemurro, F et al.
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is
posted here by agreement between Elsevier and the University of Turin. Changes resulting
from the publishing process - such as editing, corrections, structural formatting, and other
quality control mechanisms - may not be reflected in this version of the text. The definitive
version of the text was subsequently published in MOLECULAR ONCOLOGY, Feb;8,
2014, 10.1016/j.molonc.2013.08.013.
You may download, copy and otherwise use the AAM for non-commercial purposes
provided that your license is limited by the following restrictions:
(1) You may use this AAM for non-commercial purposes only under the terms of the
CC-BY-NC-ND license.
(2) The integrity of the work and identification of the author, copyright owner, and
publisher must be preserved in any copy.
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en),
10.1016/j.molonc.2013.08.013
The definitive version is available at:
http://linkinghub.elsevier.com/retrieve/pii/S1574789113001245
Potential biomarkers of long-term benefit from single-agent trastuzumab or 
lapatinib in HER2-positive metastatic breast cancer 
• Filippo Montemurro  
• Aleix Prat  
• Valentina Rossi  
• Giorgio Valabrega  
• Jeff Sperinde  
• Caterina Peraldo-Neia  
• Michela Donadio  
• Patricia Galván  
• Anna Sapino 
• Massimo Aglietta 
• José Baselga 
• Maurizio Scaltriti 
 
Highlights 
•A subset of HER2-positive breast cancer patients is exquisitely sensitive to anti-HER2 therapy. 
•We identified biomarkers of response to anti-HER2 therapy in patients not treated with 
concomitant chemotherapy. 
•The PAM50 HER2-enriched gene expression profile was associated with clinical benefit from 
anti-HER2 agents. 
•High HER2/p95 HER2 expression ratio also correlated with clinical benefit from anti-HER2 
agents. 
Abstract 
In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the 
activity of HER2-targeting agents without chemotherapy (CT) in HER2-positive metastatic 
breast cancer (MBC) patients. The primary tumors of the patients enrolled in this study offered 
a unique opportunity to identify biomarkers that could predict durable clinical benefit from CT-
free anti-HER2 therapy. 
Patients with HER2-positive MBC were randomized to trastuzumab or lapatinib as first-line 
therapy. CT was added to anti-HER2 therapy in patients failing to achieve tumor regression at 
the 8-week evaluation and in those progressing at any time. Expression analysis of 105 
selected genes was performed from formalin-fixed paraffin-embedded primary tumor samples. 
The research-based PAM50 intrinsic subtypes were also identified. Additionally, quantitative 
HER2 (H2T) and p95HER2 (p95) protein expression were evaluated by HERmark® and 
VeraTag® assay, respectively. Predictors of persistence on protocol (PP) were studied by Cox 
univariate and multivariate analysis. 
Nineteen patients were enrolled. Median overall survival was 43 months and median PP was 
3.8 months (0.8–38.8+), with 4 patients (21.1%) persisting on single agent trastuzumab or 
lapatinib for longer than 12 mo (14.9–38.8 + mo). Seventeen patients were evaluable for PP. 
Gene expression analysis revealed that high expression of the 17q12-21 amplicon 
genes HER2 and GRB7, and the PAM50 HER2-enriched intrinsic profile, were significantly 
associated with longer PP. Conversely, high expression of luminal-related genes such 
as PGR, MDM2 or PIK3CA, or the PAM50 luminal intrinsic profile correlated with reduced PP. 
Moreover, increasing H2T/p95 ratio was found to be significantly associated with longer PP (HR 
0.56 per 2-fold increase in H2T/p95, P = 0.0015). 
Our data suggest that patients belonging to the “HER2-enriched” subtype and/or having high 
H2T/p95 protein expression ratio are exquisitely sensitive to anti-HER2 agents. MBC patients 
with these tumors could be candidates for studies aimed at establishing chemotherapy-free 
regimens. 
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PFS, progression-free survival;  
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1. Introduction 
Overexpression and/or amplification of the Human Epidermal Growth Factor Receptor 2 
(HER2), found in 15–20% of breast cancers, is associated with adverse prognostic factors 
(Slamon et al., 1987 and Yarden and Sliwkowski, 2001). However, the introduction of 
trastuzumab, the first monoclonal antibody specifically designed to target HER2-positive 
(HER2+) breast cancer, has drastically improved the course of this disease both in the 
metastatic and adjuvant settings (Slamon et al., 2001, Marty et al., 2005, Romond et al., 
2005 and Piccart-Gebhart et al., 2005). Furthermore, a number of additional compounds that 
target this receptor, such as the HER2/EGFR tyrosine kinase inhibitor lapatinib, have been 
found effective in HER2+ breast cancer (Geyer et al., 2006, Cortes et al., 2009, Baselga et al., 
2012a and Verma et al., 2012). 
Overall, anti-HER2 agents are more effective when combined with chemotherapy (Pegram 
et al., 2004). However, the few clinical trials of single agent trastuzumab or lapatinib without 
chemotherapy showed that in the ∼25% of patients who responded to treatment, disease 
control duration approached that observed in trials where anti-HER2 therapy was combined 
with chemotherapy (Vogel et al., 2002 and Gomez et al., 2008). The identification of 
biomarkers that can predict which patients derive the largest benefit from chemotherapy-free 
anti-HER2 therapy would, therefore, significantly improve the management of this disease. 
On these premises, in 2009 a phase II randomized chemotherapy-free trial was initiated, 
consisting of first-line therapy with either trastuzumab or lapatinib for previously untreated, 
HER2-positive metastatic breast cancer patients (HERceptin LAPatinib-HERLAP 
trial, NCT00842998). Because of slow accrual and emerging data regarding the efficacy of dual 
HER2 blockade (Blackwell et al., 2012), the HERLAP trial was closed with 19 patients recruited. 
However, despite this small number of patients, the HERLAP trial population provides a unique 
opportunity to study predictors of long-term efficacy of single agent anti-HER2 therapy. Here 
we report our findings based on gene expression and protein expression analyses correlated 
with benefit from single-agent anti-HER2 therapy. 
2. Patients and methods 
2.1. Patient population 
The HERLAP study is a randomized, open label, phase II trial. Women with fluorescence in 
situhybridization (FISH)-proven HER2-amplified metastatic breast cancer not previously 
treated with chemotherapy and/or anti-HER2 agents for metastatic disease were eligible 
provided that they had “low burden” disease. This was defined by absence of carcinomatous 
lymphangitis and, in case of liver metastases, less than one third of the liver volume involved 
with disease. Baseline left ventricular ejection fraction (LVEF) had to be >55%. Furthermore, 
performance status (PS) had to be ≤ 2 according to the Eastern Cooperative Oncology Group 
(ECOG) definition. To be considered for the study women had to have at least one measurable 
lesion according to the Response Evaluation Criteria in solid Tumors (RECIST) version 1.0 
( Therasse et al., 2000). Lymph nodal metastases were allowed if they were the only 
metastatic sites, provided that their diameter could be measured by a CT scan. 
2.2. Treatments 
After providing written informed consent, eligible patients were randomized to either 
trastuzumab (8 mg/kg on loading dose, followed by weekly trastuzumab at the dose of 
2 mg/kg) or to oral lapatinib at the dose of 1500 mg daily with no interruptions. Treatment 
was administered for 8 weeks. After the first cycle of therapy (8 weeks), women underwent an 
imaging procedure to assess tumor response. Women who achieved minimal response (MR, 
any reduction in the sum of the largest diameters of the target lesions not fulfilling the 
definition of partial remission-PR), partial PR or complete remission (CR) were allowed to 
proceed further on single agent therapy for another 8-week cycle. Patients experiencing stable 
disease (SD) or progressing disease (PD) were considered protocol failures and continued the 
same anti-HER2 agent and chemotherapy (three weekly docetaxel, weekly paclitaxel, or 
vinorelbine if they were on trastuzumab, and capecitabine, weekly paclitaxel or vinorelbine if 
they were on lapatinib) was added. Patients experiencing significant toxicity with one agent 
could be switched to the other agent in combination with chemotherapy and were considered 
protocol failures. Women continuing on single-agent anti-HER2 therapy were restaged every 8 
weeks and allowed to proceed further if not progressing. Chemotherapy was added to anti-
HER2 therapy in women showing progressive disease. 
2.3. Safety and dose-reductions 
Safety was assessed clinically and by laboratory exams every 3 weeks or shorter if needed. 
Left ventricular ejection fraction was assessed at the baseline and every 12 weeks thereafter 
during the whole exposure to anti-HER2 therapy. No dose reductions were allowed for 
trastuzumab. In case of lapatinib-related toxicity, the dose could be de-escalated to 
1250 mg/daily. Treatment was interrupted in those patients experiencing significant (grade 
III) lapatinib-related toxicity after dose-de-escalation. Women not tolerating lapatinib were 
switched to trastuzumab plus chemotherapy. 
2.4. Gene expression data 
RNA was purified from formalin-fixed paraffin-embedded (FFPE) tissue using the Roche 
HighPure FFPE Micro Kit, and ∼100 ng of total RNA was used to measure expression of 110 
selected genes using the nCounter Nanostring platform. The selected gene list includes the 50 
PAM50 genes, genes associated with VEGF/hypoxia-related biological processes (e.g. VEGF and 
ADM), proliferation/cell-cycle (e.g. MKI67 and CCNB1), EGFR signaling (e.g. EGFR, ERBB4) and 
epithelial-to-mesenchymal transition (e.g. CLDN3 and EPCAM). Raw data was log base 2 
transformed and normalized using 5 house-keeping transcripts. 
All tumors were assigned to an intrinsic molecular subtype of breast cancer (Luminal A, 
Luminal B, HER2-enriched, Basal-like) and the Normal-like group using the PAM50 subtype 
predictor as previously described (Parker et al., 2009). For PAM50 platform-to-platform 
normalization, a total of 53 primary breast samples representing all the intrinsic molecular 
subtypes were also profiled using the same procedures as described above. 
Eight genomic signatures were evaluated individually from the PAM50 subtype predictor output 
data (Parker et al., 2009, Nielsen et al., 2010 and Prat et al., 2013). These signature were the 
correlation of each sample to each of the 5 PAM50 tumor centroids (Luminal A, Luminal B, 
HER2-enriched, Basal-like and Normal), the previously reported Proliferation score, which is 
the mean expression of 11 proliferation-related genes (Nielsen et al., 2010), and the risk of 
relapse (ROR) score based on subtype only (ROR-S), and based upon subtype and proliferation 
(ROR-P). 
All gene expression data has been deposited in GEO (accession number GSE46350). 
2.5. HER2 and p95 protein expression quantification 
Quantitative HER2 protein expression (H2T) was obtained using the HERmark assay. (Huang 
et al., 2010) The quantitative p95 protein assay which is specific for the active form of p95, 
was performed as previously described (Sperinde et al., 2010). Tumor average expression was 
reported in units of relative fluorescence per square millimeter of tumor (RF/mm2). 
2.6. Statistical considerations 
The original sample size calculation for the HERLAP trial is described in Supplementary data 1. 
For the current study, persistence on protocol (PP) was chosen ad hoc as the clinical outcome 
of interest. Persistence on protocol was defined as time from randomization to addition of 
chemotherapy or death from any cause. We considered this endpoint as a surrogate for benefit 
from single-agent anti-HER2 therapy. Additionally, we calculated progression-free survival 
(PFS) as the interval from randomization to disease progression or death from any cause, and 
overall survival (OS) as the interval from randomization to death from any cause. 
Analyses were conducted in January 2013, at a median overall follow-up of 32 months (range 
14–81 months). Expression values (genes or proteins) were analyzed as continuous variables. 
Where appropriate, continuous variables were dichotomized around their median values. 
Estimates of survival and PP were obtained by Kaplan–Meier curves and tests of differences by 
the log-rank test. The association between gene expression, gene signature expression, HER2 
and p95 protein levels and PP was assessed by Cox proportional regression analysis. 
In the analyses, a Hazard Ratio (HR) < 1 indicated longer persistence on protocol (i.e. reduced 
probability of adding chemotherapy). All tests were two tailed. Due to the small sample size 
and the purely exploratory intent of this analysis, no correction was applied for multiple 
testing. 
3. Results 
3.1. Clinical outcome 
A total of 19 patients were enrolled in the HERLAP trial. Nine and 10 patients were randomly 
assigned to single agent trastuzumab and lapatinib, respectively. A summary of the clinical-
pathological data of the patients is shown in Table 1. Two patients in the lapatinib arm 
discontinued protocol before the first evaluation due to grade 3 diarrhea (one patient), and 
grade 3 skin toxicity (one patient) that did not improve after dose reduction. Upon resolution 
of toxicities, both patients were switched to trastuzumab with chemotherapy consisting of 
vinorelbine (30 mg/m2 on days 1 and 8 every 3 weeks) in one, and in docetaxel 
(75 mg/m2 every 3 weeks) in the other. Seventeen patients were therefore evaluable for 
benefit from single-agent anti-HER2 therapy. 
Table 1. Clinical-pathological characteristics of the patient population 
Variable Number (percentages o range) 
Total enrolled 19 
Median age (years) 59 (36–76) 
Stage at first diagnosis 
I/II 11 (58) 
III 3 (16) 
IV 5 (26) 
HER2 status 
 HER2 3+/FISH+ 16 (84) 
 HER2 2+/FISH+ 3 (16) 
ER and/or PgR status 
 Positive 12 (63) 
 Negative 7 (37) 
Mean Ki67 40 (14–70)a 
Prior treatment 
 Prior neo/adjuvant chemotherapy 10 (53) 
 Adjuvant anthracycline 10 (53) 
 Adjuvant taxane 6 (32) 
 Adjuvant trastuzumab 5 (26) 
 Adjuvant endocrine therapy 7 (37) 
Number of sites of metastatic disease 
 1 5 (26) 
 2 7 (37) 
 3 6 (32) 
 4 1 (5) 
Metastatic sites 
 Liver 4 (21) 
 Lung 12 (63) 
Variable Number (percentages o range) 
 Lymph-node/soft tissue 16 (84) 
 Bone 7 (37) 
 Effusions 1 (5) 
Type of site 
 Visceral (liver + lung) 14 (74) 
 Non visceral 5 (26) 
Treatment allocation 
 Trastuzumab 9 (47) 
 Lapatinib 10 (53) 
FISH, fluorescence in-situ hybridization, ER, estrogen receptor, PgR, progesterone receptor. 
a        For 4 patients with de-novo stage IV disease, Ki67 was not assessed on core biopsies. Women with de-
novo stage IV disease were considered as having DFS = 0. 
 
At the time of data cutoff, two patients were still on protocol receiving single-agent 
trastuzumab (persistence on protocol 14.9 and 38.8 months, respectively). Another two had 
achieved disease control that lasted at least 12 months or more. Finally, disease had not 
progressed in two patients who were considered protocol failures (one achieved a SD at the 
first evaluation and the other discontinued lapatinib because of toxicity before the first 8-week 
evaluation). Of 8 patients in the lapatinib arm failing to show response at the 8-week 
evaluation or whose disease progressed at any time during monotherapy, four received first-
line chemotherapy with capecitabine (2000 mg/m2/day for 14 days every three weeks) and 
three with vinorelbine (30 mg/m2 on days 1 and 8 every 3 weeks), both added to lapatinib 
(1250 mg/day). The remaining patient refused to undergo further HER2-targeting therapy and 
received endocrine therapy with fulvestrant. Of 7 patients in the trastuzumab arm failing to 
show response at the 8-week evaluation or with disease progression at any time during 
monotherapy, four received first-line chemotherapy with docetaxel (75–100 mg/m2 every 
three weeks), and two with vinorelbine 30 mg/m2 on days 1 and 8 every 3 weeks), both 
added to trastuzumab (either 2 mg/kg weekly or 6 mg/kg every three weeks). The remaining 
patient refused chemotherapy and was treated with exemestane and trastuzumab. 
In the overall population, median persistence on protocol, median progression-free survival 
and median overall survival were 3.8 months (range 0.77–38.8+), 7.3 months (range 1.6–
38.8+) and 43 months (14.0–81.0+), respectively. Analyses of the data from the 17 evaluable 
patients provided similar results (not shown). 
In terms of tumor response, a total of 12 evaluable patients (71%) experienced at least a MR 
at 8 weeks, 2 (12%) experienced SD, and 3 (18%) experienced PD. No significant difference in 
terms of response at 8 weeks was observed according to treatment arm (75% and 67% MR or 
more with lapatinib and trastuzumab, respectively, P = 1.0). 
3.2. Gene expression data 
The PAM50 intrinsic molecular subtypes were found associated with persistence on protocol in 
the ITT population with the HER2-enriched subtype showing an increased persistence on 
protocol than the other subtypes. Compared to patients with Luminal A and B tumors, patients 
with HER2-enriched tumors showed a significant increase in persistence on protocol (Hazard 
Ratio for protocol discontinuation [HR] = 0.208, P = 0.044). Neither ER status by IHC nor 
HER2 FISH amplification ratio was found significantly associated with persistence on protocol. 
Next, we looked for associations between the expression of each single gene, or the score of 
each signature, and persistence on protocol in the ITT population (Supplementary data 2). 
Among 113 variables (105 genes and 8 signatures), 11 (HER2, GRB7, CLDN4, RAB25, MAPT, 
CLDN7, EMP3, DDR1, MDM2, UBE2T and HER2-enriched signature) and 20 (the 11 previous 
biomarkers and PIK3CA, DSP, RRAGD, SPINT2, BCL2, CDH3, VEGFA, PVRL3 and PGR) 
variables correlated with persistence on protocol in multivariate analyses (adjusted for 
treatment arm) with a P < 0.05 and P < 0.10, respectively. Conversely, high expression of 
genes associated with the Luminal subtypes, such as MAPT (also known as Tau), BCL2 and 
PGR was found associated with decreased persistence on protocol. Interestingly, low 
expression of genes associated with the epithelial-to-mesenchymal transition such as CLDN4 
and CLDN7 were found significantly associated with a decreased persistence on protocol. 
3.3. H2T and p95 protein expression analysis 
H2T and p95 protein levels were successfully measured in 16 of the 17 patients analyzed for 
PP. Median expression values were 122.5 RF/sqmm (range 6.67–475) and 2.95 (range 0.60–
8.23) for H2T and p95, respectively. Increasing log(H2T) correlated with longer PP (HR = 0.73 
per 2-fold increase in H2T; 95% CI 0.54–1.00; p = 0.046). Log(p95) was not correlated with 
PP by univariate analysis (p = 0.97), possibly due to the association of high p95 expression 
with high H2T expression. Due to this relationship, we then calculated the H2T/p95 ratio, 
which ranged from 1.97 to 88.17 (median value 46.60). This exploratory variable was 
associated with PP, with an HR of 0.56 per 2-fold change in H2T/p95 (95% CI 0.37–
0.84;p = 0.0015). This translates into a 44% reduction in the risk of adding chemotherapy for 
each 2-fold increase in the ratio. Kaplan Meier analysis of PP by H2T/p95 ratio dichotomized 
around its median value showed a significantly longer PP for patients with higher values 
(HR = 0.24; 95% CI 0.074–0.75;p = 0.0089) with median PP of 2.0 months vs. 9.6 months 
for below vs. above the median, respectively (Figure 1). Because of the small sample size, we 
decided not to model a multivariate analysis including gene and protein expression data. 
However the median H2T/p95 expression ratio was lower in Luminal A/B (5.22) compared with 
HER2-enriched tumors (57.72, p = 0.052) and with non-Luminal/non HER2-enriched tumors 
(65.57, p = 0.034). Table 2 summarizes the main features of the 4 patients experiencing 
persistence on protocol longer than 12 months. 
 
 
 
 
 
 
 
 
 
  
Figure 1. Kaplan Meier curves of persistence on protocol in patients with tumors 
showing H2T/p95 expression ratio values higher (solid line) or equal/lower (dotted line) 
than the median value of 46.60 
 
 
Case 
ER PgR Ki67 HER2 statusa PAM50 subtype H2T/p95 
Treatment Time on protocol (months) (%) (%) (%) Ratio 
1 0 0 Unk 3+/FISH+ HER2-enriched 67.62 Trastuzumab 38.8b 
2 97 0 32 3+/FISH+ HER2-enriched 58.38 Trastuzumab 25.3 
3 0 0 14 3+/FISH+ HER2-enriched 18.75 Lapatinib 17.0 
4 11 12 29 3+/FISH+ Normal-like 88.17 Trastuzumab 14.9a 
A   Immunohistochemistry and Fluorescence in situ hybridization. 
B   Still on treatment at the time of this analysis. Unk, unknown. 
 
Table 2. Features of the four patients achieving disease control lasting>12 months. 
 
4. Discussion 
The HERLAP trial was designed with the aim of evaluating potential biomarkers of long-term 
benefit from HER2-inhibition not confounded by concomitant chemo or endocrine therapy in 
the metastatic setting. Currently, data regarding the activity of chemotherapy-free, anti-HER2 
therapy have been mainly generated from the preoperative setting (Gianni et al., 
2012, Rimawi et al., 2013a and Prat and Baselga, 2013). In two randomized clinical trials, a 
significant proportion of HER2-positive early breast cancer achieved primary disease 
eradication by multiple HER2 targeting alone, (Gianni et al., 2012) or in combination with 
endocrine therapy (Rimawi et al., 2013b). In the metastatic setting, trials testing the efficacy 
of anti-HER2 therapy followed by addition of chemotherapy in a classical sequential fashion 
have provided results that have rather discouraged this approach (Hamberg et al., 
2011 and Inoue et al., 2010). Unlike these randomized studies, the HERLAP trial enrolled 
patients with metastatic disease (low-burden) and allowed them to proceed on single-agent 
anti-HER2 therapy only if radiological signs of tumor regression could be registered after 8 
weeks. Importantly, this design did not negatively affect the clinical outcomes of the patients 
enrolled in our study. In fact, their overall survival was similar to that reported with 
chemotherapy combined with single-agent anti-HER2 therapy (Marty et al., 2005 and Baselga 
et al., 2012a). This suggests that the strategy of starting anti-HER2 therapy and adding 
chemotherapy in non-responding patients is safe and could be considered in clinical practice. 
Overall, gene expression data suggest that the “HER2-enriched” intrinsic subtype identified by 
gene expression analysis, or high ERBB2 and low ESR1 gene expression, can identify patients 
with tumors more likely to be successfully controlled by single agent trastuzumab or lapatinib. 
Conversely, tumors of the “luminal” subtype, or tumors with low expression of CLDN4 and 
CLDN7 (the so-called “claudin-low” subtype) (Prat et al., 2010), were less likely to benefit from 
anti-HER2 treatment alone. Our data are corroborated by recent data showing that, in the 
neoadjuvant setting, HER2-enriched tumors achieve higher pathological complete response 
rate following anti-HER2 therapy compared to the other subtypes (Carey et al., 2013). 
Moreover, this study confirmed the heterogeneity of molecular subtypes among the tumors 
classified as HER2-positive. This heterogeneity was further mirrored by the measurements of 
the total and truncated HER2 receptors in the primary tumors of the patients enrolled in our 
study. As expected, the levels of total HER2 positively correlate with benefit from anti-HER2 
therapy and high HER2 levels were coincided with a molecular HER2-enriched signature. Our 
analysis has limitations due to the small number involved and the fact that a half of the 
patients received trastuzumab and the other half lapatinib. Combining the two groups was a 
necessary choice that we considered reasonable due to the fact that no difference emerged in 
the efficacy of the two treatments. The small sample size limited also the extent and quality of 
statistical analyses. However, our results reconcile a growing body of evidence suggesting that 
the heterogeneity of HER2-positive breast cancer, which has been known for a long time 
(Perou et al., 2000), has a potentially substantial impact on clinical decision making. The most 
remarkable example regards co-expression of hormone receptors that identifies a subgroup 
with a different clinical behavior, response to chemotherapy and potential for specific 
therapeutic strategies (Gianni et al., 2012, Rimawi et al., 2013a, Montemurro et al., 
2012, Baselga et al., 2012b and Vaz-Luis et al., 2013). Further studies will likely provide 
evidence of more complex biological heterogeneity and reveal a rationale for of specific 
treatment strategies. Along this line, although preliminary and needing confirmation, we 
believe that our data add an important piece of information in the increasingly diversified 
management of HER2-positive breast cancer. 
5. Conclusions 
For the first time in the metastatic setting we show that a true “HER2-enriched” gene 
expression status and/or a high ratio of H2T/p95 protein expression may represent a profile of 
clinical addiction to HER2 and a prerequisite for maximized benefit from targeting agents. 
HER2-positive tumors deviating from this definition may need combined treatments (anti-HER2 
therapy with chemotherapy and/or perhaps endocrine therapy) to achieve optimal control. 
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